BCM
UBX

Bridgeway Capital Management’s Unity Biotechnology UBX Stock Holding History

Bridgeway Capital Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,000
Closed -$9.5K – 1287
2025
Q2 		$9.5K Sell
25,000
-25,000
-50% -$21.4K ﹤0.01% 1175
2025
Q1 		$52K Hold
50,000
– – ﹤0.01% 1117
2024
Q4 		$48.8K Buy
50,000
+25,000
+100% +$31.1K ﹤0.01% 1158
2024
Q3 		$36.8K Hold
25,000
– – ﹤0.01% 1228
2024
Q2 		$33.8K Sell
25,000
-25,000
-50% -$38K ﹤0.01% 1244
2024
Q1 		$82K Hold
50,000
– – ﹤0.01% 1226
2023
Q4 		$96.5K Hold
50,000
– – ﹤0.01% 1246
2023
Q3 		$120K Hold
50,000
– – ﹤0.01% 1194
2023
Q2 		$128K Hold
50,000
– – ﹤0.01% 1218
2023
Q1 		$81.5K Sell
50,000
-10,705
-18% -$42.9K ﹤0.01% 1265
2022
Q4 		$166K Buy
60,705
+50,000
+467% +$145K ﹤0.01% 1131
2022
Q3 		$42K Sell
10,705
-8,440
-44% -$53.2K ﹤0.01% 1361
2022
Q2 		$108K Sell
19,145
-4,500
-19% -$37.5K ﹤0.01% 1212
2022
Q1 		$265K Buy
23,645
+2,800
+13% +$31.4K 0.01% 1115
2021
Q4 		$304K Sell
20,845
-5,800
-22% -$127K 0.01% 1100
2021
Q3 		$799K Buy
26,645
+23,600
+775% +$833K 0.02% 887
2021
Q2 		$141K Hold
3,045
– – ﹤0.01% 1294
2021
Q1 		$183K Hold
3,045
– – ﹤0.01% 1291
2020
Q4 		$160K Buy
+3,045
New +$147K ﹤0.01% 1234

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Bridgeway Capital Management's UBX Position: Q3 2025 in Review

Bridgeway Capital Management sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 25,000 shares — an estimated $9.5K sold.

Bridgeway Capital Management first reported a position in UBX in Q4 2020 and held it in 19 quarters. The position peaked at $799K in Q3 2021. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • Bridgeway Capital Management reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 25,000 Unity Biotechnology shares in Q3 2025, an estimated $9.5K.
  • Bridgeway Capital Management first reported a position in Unity Biotechnology in Q4 2020 and held it in 19 quarters.
  • Bridgeway Capital Management's Unity Biotechnology position peaked at $799K in Q3 2021.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Bridgeway Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.